The genes can help predict a person's risk of developing disease with approximately 78 % accuracy, and could be targeted
by molecular diagnostic tests.
Not exact matches
Straticyte is the first and only
molecular diagnostic test for oral precancerous lesions that provides an objective and accurate prediction score as evidenced
by retrospective clinical studies.
Since December 2010, WHO has endorsed the Xpert MTB / RIF
test, a new
molecular diagnostic manufactured
by Cepheid, a company based in Sunnyvale, California.
Although doctors have long incorporated personal information like family history into treatment plans, personalized medicine holds the promise of revolutionizing medical care
by using knowledge of
molecular biology and genetics that will allow more precise diagnoses, better
diagnostic tests, greater predictability of disease course, more successful therapies
by targeting the right treatments to the right patients, and improved patient safety
by selecting drugs and their proper dosage to reduce adverse side effects.
RBM's initial
molecular diagnostic test, VeriPsychTM, is a blood - based
test that aids in the confirmation of diagnosis of recent - onset schizophrenia
by evaluating a proprietary set of 51 biomarkers.
Invivoscribe Technologies Inc. is a privately held biotechnology company dedicated to improving the quality of healthcare worldwide
by providing high quality, reliable, cutting - edge reagents,
tests, and bioinformatics tools to advance the fields of personalized
molecular diagnostics ® and personalized
molecular medicine.
SAN DIEGO, March 28, 2017 (GLOBE NEWSWIRE)-- Invivoscribe ® Technologies Inc., a global company with decades of experience providing internationally standardized clonality and biomarker
testing solutions for the fields of oncology, personalized
molecular diagnostics ®, and personalized
molecular medicine ®, reports that its next - generation sequencing (NGS) LymphoTrack ® Assay kits are being used
by its LabPMM ® clinical laboratories, pharmaceutical partners, and cancer centers to identify and monitor chimeric antigen receptor T - cells (CAR - T) and engineered T - cell receptors in peripheral blood of subjects in support of immuno - therapeutic drug development and treatment regimen development for both hematologic and solid tumors.